Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis

Multiple Sclerosis Journal

Volumn 19, Issue 5, 2013, Pages 593-600

  Vennegoor, Anke ^a   Rispens, Theo ^b   Strijbis, Eva M M ^a   Seewann, Alexandra ^a   Uitdehaag, Bernard M J ^a   Balk, Lisanne J ^a   Barkhof, Frederik ^a   Polman, Chris H ^a   Wolbink, Gertjan ^b,c   Killestein, Joep ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SANQUIN RESEARCH   (Netherlands)

^c JAN VAN BREEMEN INSTITUTE   (Netherlands)

Author keywords

antibodies; Multiple sclerosis; natalizumab; natalizumab concentration

Indexed keywords

DRUG ANTIBODY; NATALIZUMAB; NATALIZUMAB ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BLOOD SAMPLING; CLINICAL EVALUATION; COHORT ANALYSIS; COMPLEX FORMATION; DISEASE ACTIVITY; DISEASE DURATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TREATMENT FAILURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; RADIOIMMUNOASSAY; RECURRENCE RISK; RELAPSE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84876530257     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512460604     Document Type: Article

References (19)

1. Yednock TA, Cannon C, Fritz LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature. 1992 ; 356: 63-66.
2. Stüve O, Bennett JL. Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri®) in inflammatory diseases. CNS Drug Rev. 2007 ; 13: 79-95
3. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 ; 354: 899-910
4. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006 ; 354: 911-923.
5. Polman CH, Bertolotto A, Deisenhammer F, et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol. 2010 ; 9: 740-750
6. Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006 ; 54: 711-715
7. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003 ; 348: 601-608
8. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti- adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007 ; 66: 921-926
9. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011 ; 305: 1460-1468
10. Farrell RA, Giovannoni G. Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis. Mult Scler. 2007 ; 13: 567-577
11. Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology. 2007 ; 69: 1391-1403
12. Oliver B, Fernandez O, Orpez T, et al. Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months. Mult Scler. 2011 ; 17: 368-371
13. Sorensen PS, Jensen PE, Haghikia A, et al. Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. Mult Scler. 2011 ; 17: 1074-1078
14. Jensen PE, Koch-Henriksen N, Sellebjerg F, et al. Prediction of antibody persistency from antibody titres to natalizumab. Mult Scler. 2012 ;:
15. Rispens T, Leeuwen A, Vennegoor A, et al. Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody. Anal Biochem. 2011 ; 411: 271-276
16. Khatri BO, Man S, Giovannoni G, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology. 2009 ; 72: 402-409
17. Rispens T, de Vrieze H, de Groot E, et al. Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing. J Immunol Methods. 2012 ; 375: 93-99
18. Hart MH, de Vrieze H, Wouters D, et al. Differential effect of drug interference in immunogenicity assays. J Immunol Methods. 2011 ; 372: 196-203
19. Van der Laken CJ, Voskuyl AE, Roos JC, et al. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis. 2007 ; 66: 253-256